Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer

Faisal Shahjehan, Saivaishnavi Kamatham, Ashton Ritter, Pashtoon Murtaza Kasi, Faisal Shahjehan, Saivaishnavi Kamatham, Ashton Ritter, Pashtoon Murtaza Kasi

Abstract

Doublet chemotherapies are the mainstay in the management of metastatic anal cancer. Immunotherapy has been incorporated into guidelines in a refractory setting. Treatment options remain limited with tumor progression beyond immunotherapy. Modified docetaxel, cisplatin, and fluorouracil (mDCF) chemotherapy, after progression postimmunotherapy, has shown a near-complete response in our patient with metastatic anal cancer. This likely is secondary to the sequence of immunotherapy followed by chemotherapy that is yielding greater than historical responses.

Keywords: chemotherapy; cisplatin; fluorouracil; immunotherapy; mDCF; metastatic anal cancer; modified docetaxel.

Conflict of interest statement

Consulting/Advisory board: PMK (Ipsen/Taiho to institution). Research Funding (To institution)—Advanced Accelerator Applications; Array BioPharma; Bristol‐Myers Squibb; Celgene. No other conflicts of interests to report for the authors.

Figures

Figure 1
Figure 1
CT scans of the patient before modified‐ docetaxel, cisplatin, and fluorouracil (DCF) chemotherapy showing multiple lung metastases
Figure 2
Figure 2
CT scans showing a near‐complete resolution of lung metastases after modified‐ docetaxel, cisplatin, and fluorouracil (DCF) chemotherapy

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7‐30.
    1. Islami F, et al. International trends in anal cancer incidence rates. Int J Epidemiol. 2017;46(3):924‐938.
    1. Society, A.C . Anal Cancer Survival Rates 2017. Available from .
    1. Kim S, François E, André T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes‐HPV02): a multicentre, single‐arm, phase 2 study. Lancet Oncol. 2018;19(8):1094‐1106.
    1. Dwary AD, Master S, Patel A, et al. Excellent response to chemotherapy post immunotherapy. Oncotarget. 2017;8(53):91795‐91802.
    1. Baraibar Argota P, Sanmamed MF, et al.Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors in MAP 2018 ‐ Molecular Analysis for Personalised Therapy. 2018. ESMO.
    1. Chakrabarti S, Dong H, Paripati HR, Ross HJ, Yoon HH. First report of dramatic tumor responses with ramucirumab and paclitaxel after progression on pembrolizumab in two cases of metastatic gastroesophageal adenocarcinoma. Oncologist. 2018;23(7):840‐843.
    1. Goldinger SM, Lo S, Hassel JC, et al. The utility of chemotherapy after immunotherapy failure in metastatic melanoma: a multicenter case series. J Clin Oncol. 2018;36(15_suppl):e21588‐e21588.
    1. Park SE, Lee SH, Ahn JS, Ahn M‐J, Park K, Sun J‐M. Increased response rates to salvage chemotherapy administered after pd‐1/pd‐l1 inhibitors in patients with non‐small cell lung cancer. J Thorac Oncol. 2018;13(1):106‐111.
    1. Shiono A, Kaira K, Mouri A, et al. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients. Thorac Cancer. 2019;10(4):775‐781.
    1. Cummings BJ. Metastatic anal cancer: the search for cure. Onkologie. 2006;29(1–2):5‐6.
    1. Yellu M, Deeb A, Olowokure O. Overview of recent trends in the management of metastatic anal cancer. World J Oncol. 2015;6(1):311‐315.
    1. Kin C. So now my patient has squamous cell cancer: diagnosis, staging, and treatment of squamous cell carcinoma of the anal canal and anal margin. Clin Colon Rectal Surg. 2018;31(6):353‐360.
    1. Hung A, Crane C, Delclos M, et al. Cisplatin‐based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003;97(5):1195‐1202.
    1. Allal AS, Mermillod B, Roth AD, Marti M‐C, Kurtz JM. Impact of clinical and therapeutic factors on major late complications after radiotherapy with or without concomitant chemotherapy for anal carcinoma. Int J Radiat Oncol Biol Phys. 1997;39(5):1099‐1105.
    1. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer. 1986;58(3):611‐616.
    1. Patel HS, Silver AR, Northover JM. Anal cancer in renal transplant patients. Int J Colorectal Dis. 2007;22(1):1‐5.
    1. Kang J, Min BS, Lee KY, Jang SJ, Kim WH, Kim NK. Squamous cell carcinoma of the anus in a patient with perianal Crohn's disease. Int J Colorectal Dis. 2010;25(3):411‐413.
    1. Devon KM, Brown CJ, Burnstein M, McLeod RS. Cancer of the anus complicating perianal Crohn's disease. Dis Colon Rectum. 2009;52(2):211‐216.
    1. Frisch M, Glimelius B, van den Brule A, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350‐1358.
    1. Mitra S, Crane L. Diagnosis, treatment, and prevention of anal cancer. Curr Infect Dis Rep. 2012;14(1):61‐66.
    1. Frisch M, et al. Tobacco smoking as a risk factor in anal carcinoma: an antiestrogenic mechanism? J Natl Cancer Inst. 1999;91(8):708‐715.
    1. Daling JR, Sherman KJ, Hislop TG, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol. 1992;135(2):180‐189.
    1. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270‐280.
    1. Cui A, Mei Z, Cui L. Anal malignant proliferative trichilemmoma: report of a rare case with review of literature. Int J Clin Exp Pathol. 2015;8(3):3349‐3353.
    1. Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014;5(22):11133‐11142.
    1. Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989;87(2):221‐224.
    1. Faivre C, et al. 5‐fluororacile and cisplatinum combination chemotherapy for metastatic squamous‐cell anal cancer. Bull Cancer. 1999;86(10):861‐865.
    1. Tanum G. Treatment of relapsing anal carcinoma. Acta Oncol. 1993;32(1):33‐35.
    1. Rao S, S.F., Eng C,, et al.Carboplatin Plus Paclitaxel Represents a New Standard of Care for Patients with Squamous Cell Carcinoma of the Anal Canal. 2018; Available from .
    1. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single‐arm, phase 2 study. Lancet Oncol. 2017;18(4):446‐453.
    1. Ott PA, Piha‐Paul SA, Munster P, et al. Safety and antitumor activity of the anti‐PD‐1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28(5):1036‐1041.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel